Back to Results
First PageMeta Content
Monoclonal antibodies / AstraZeneca / Södertälje Municipality / Biologic / Pharmaceutical industry / TNF inhibitor / Pharmacology / Pharmaceutical sciences / Biotechnology


Avaxia Biologics Appoints Deborah S. Hartman, Ph.D. as Vice President, Research LEXINGTON, Mass. – March 26, 2013 – Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeut
Add to Reading List

Document Date: 2014-02-06 00:38:28

Open Document

File Size: 94,04 KB

Share Result on Facebook

City

LEXINGTON / Basel / /

Company

Avaxia Biologics Inc. / Lead Generation DECS / AstraZeneca Pharmaceuticals / Contacts Avaxia Biologics Inc. / Respiratory & Inflammation Research UK / /

Country

Switzerland / /

/

Event

FDA Phase / Employment Change / /

Facility

Princeton University / Yale University / /

IndustryTerm

biopharmaceutical / pharmaceutical research / technology / clinical stage product / /

MedicalCondition

serious diseases / nervous system diseases / celiac disease / inflammatory bowel disease / GI acute radiation syndrome / disease / oral mucositis / diabetes / active ulcerative colitis / infectious diseases / /

MedicalTreatment

radiation / /

Organization

Princeton University / Yale University / /

Person

Barbara S. Fox / Dan Tracey / Charles Liles / Deborah S. Hartman / Jen Conrad / Michael D. Rivard / /

/

Position

CEO / leader / Vice President / Chief Executive Officer / Project Leader and Principal Scientist / Vice President of Projects / VP Corporate Development / Vice President / Research / consultant / Vice President / Research / scientist and senior executive / /

Product

AVX-470 / /

ProvinceOrState

Massachusetts / /

PublishedMedium

Molecular Biology / /

Technology

radiation / /

URL

www.avaxiabiologics.com / /

SocialTag